Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Dense Docetaxel Followed by T-AC in Breast Cancer
NCT00193115Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Mar 2004
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of docetaxel in breast cancer (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Treatment-related toxicities. Started Mar 2004; status: completed.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00193115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193115.